Ocular Therapeutix, Inc.
OCUL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15 | $13 | $11 | $17 |
| % Growth | 8.1% | 25.8% | -37.4% | – |
| Cost of Goods Sold | $2 | $2 | $1 | $1 |
| Gross Profit | $13 | $12 | $9 | $16 |
| % Margin | 87.8% | 85.6% | 88.2% | 92.8% |
| R&D Expenses | $52 | $51 | $43 | $41 |
| G&A Expenses | $0 | $27 | $29 | $24 |
| SG&A Expenses | $29 | $28 | $30 | $25 |
| Sales & Mktg Exp. | $0 | $2 | $2 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $81 | $79 | $73 | $66 |
| Operating Income | -$69 | -$68 | -$64 | -$51 |
| % Margin | -472.3% | -502.6% | -597.5% | -296.1% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | $2 |
| Pre-Tax Income | -$69 | -$68 | -$64 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69 | -$68 | -$64 | -$48 |
| % Margin | -477.3% | -503.9% | -598.7% | -283.3% |
| EPS | -0.38 | -0.39 | -0.38 | -0.29 |
| % Growth | 2.6% | -2.6% | -31% | – |
| EPS Diluted | -0.38 | -0.39 | -0.38 | -0.29 |
| Weighted Avg Shares Out | 184 | 173 | 169 | 168 |
| Weighted Avg Shares Out Dil | 184 | 173 | 169 | 168 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $4 | $5 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$65 | -$64 | -$60 | -$44 |
| % Margin | -449.3% | -473.8% | -561.7% | -259.5% |